Survodutide

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.278

Reference number

10mg

Lyophilized vial

Origin

Survodutide (BI 456906) was developed by Boehringer Ingelheim and Zealand Pharma as a glucagon/GLP-1 receptor dual agonist derived from oxyntomodulin. It is engineered with a bias toward glucagon receptor activation relative to GLP-1, distinguishing it from GLP-1-dominant dual agonists.

Research Lineage

Nahra et al. published Phase II results in Diabetes Care (2024) demonstrating effects on body weight and metabolic parameters. Boehringer Ingelheim is conducting Phase III trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). The glucagon-biased profile is being investigated for its potential effects on hepatic lipid metabolism.

Mechanism of Action

Survodutide activates both GLP-1 and glucagon receptors, with a ratio favoring glucagon receptor activation. Glucagon receptor agonism in hepatocytes has been observed to increase fatty acid oxidation and reduce de novo lipogenesis. The GLP-1 component contributes appetite reduction and improved glycemic control. This dual mechanism targets both energy intake (GLP-1) and hepatic lipid handling (glucagon).

Structural Notes

Acylated peptide analog. Oxyntomodulin-derived backbone with chemical modifications for metabolic stability and optimized receptor selectivity.